Bolt - BOLT

Short interest for Bolt Biotherapeutics gives investors a sense of the degree to which investors are betting on the decline of Bolt Biotherapeutics's stock. Short interest data is updated every two weeks.

Bolt Biotherapeutics Stock (NASDAQ:BOLT), Short Interest Report

Bolt Biotherapeutics

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACAQ

AWIN

BITF

BNOX

BOLT

BROG

BTTR

CNTX

EMKR

FEMY

GROM

Intelligent Bio Solutions Inc. - Common Stock

INBS

OGEN

RSLS

RVLP

SNDX

SYTA

Gainers


	AERWINS Technologies Inc.  (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not limited to possible sale/other disposition of assets.


Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

General

RHHBY

Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies

Price Target

Analyst Ratings

APTV

BMBL

JACK

XMTR


	SVB Leerink cut the price target on  Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) from $8 to $4. SVB Leerink analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Bolt Biotherapeutics shares fell 3.2% to $2.44 in pre-market trading.


SVB Leerink Cuts Price Target On This Stock By 50%, Also Check Out Some Other Major PT Changes

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics Inc

Bolt Metals Corp

Bolt Projects Holdings Inc

<h3>Gainers</h3>
<ul>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares rose 8.46% to $0.58. The company's market cap stands at $6.3 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares increased by 6.74% to $40.99. The market value of their outstanding shares is at $818.4 million. As per the news, the Q2 earnings report came out today. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares moved upwards by 6.66% to $1.44. The company's market cap stands at $54.9 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares increased by 6.66% to $1.76. The market value of their outstanding shares is at $2.6 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares rose 5.38% to $4.5. The company's market cap stands at $236.2 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) shares fell 10.8% to $1.9 during Wednesday's after-market session. The company's market cap stands at $104.6 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock fell 10.4% to $1.81. The market value of their outstanding shares is at $2.2 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares decreased by 8.54% to $2.25. The market value of their outstanding shares is at $181.8 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares declined by 8.51% to $0.64. The market value of their outstanding shares is at $22.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 7.33% to $2.53. The company's market cap stands at $9.2 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares declined by 6.33% to $6.07. The company's market cap stands at $5.3 million. As per the press release, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

CNTB

EIGR

HSDT

IPHA

12 Health Care Stocks Moving In Wednesday's After-Market Session

HC Wainwright &amp; Co. analyst Edward White maintains Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Buy and maintains $8 price target.

HC Wainwright & Co. Maintains Buy on Bolt Biotherapeutics, Maintains $8 Price Target

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 11.32 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $2.09 million which beat the analyst consensus estimate of $1.71 million by 22.16 percent. This is a 48.05 percent increase over sales of $1.41 million the same period last year.

Earnings

Bolt Biotherapeutics Q4 EPS $(0.47) Beats $(0.48) Estimate, Sales $2.09M Beat $1.71M Estimate

Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody&trade; Immune-Stimulating Antibody Conjugate (ISAC), as a single agent and in combination with the HER2-targeting antibody pertuzumab.

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu

Vivo Capital VIII LLC, 10% Owner at Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), reported a large insider sell on November 21, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001641281/000121390023088909//Archives/edgar/data/1641281/000121390023088909/0001213900-23-088909-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that LLC sold 86,054 shares of Bolt Biotherapeutics. The total transaction amounted to $79,933. 
Bolt Biotherapeutics shares are trading up 1.29% at $0.93 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001641281">Check Out The Full List Of Bolt Biotherapeutics's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Bolt Biotherapeutics 10% Owner Trades $79K In Company Stock

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 25.86 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $2.53 million which beat the analyst consensus estimate of $1.72 million by 46.98 percent. This is a 19.70 percent increase over sales of $2.11 million the same period last year.

Earnings Beats

Bolt Biotherapeutics Q3 EPS $(0.43) Beats $(0.50) Estimate, Sales $2.53M Beat $1.72M Estimate

<ul>
<li>Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) &nbsp;</li>
<li>Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional patients with long-term stable disease (SD), and three patients who have now received therapy for ≥ 1 year</li>
<li>BDC-1001 continues to be well tolerated &nbsp;</li>
</ul>
REDWOOD CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated data from its Phase 1 dose-escalation trial of BDC-1001 at the European Society for Medical Oncology (ESMO) 2023 Congress, being held in Madrid, Spain and virtually from October 20-24, 2023.
BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate (ISAC) in development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive cancer. BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist. The Phase 1 dose-escalation trial enrolled 131 patients with 16 different HER2-expressing solid tumor types across 18 dose levels in two arms, monotherapy and in combination with nivolumab. At enrollment, all patients entered in the study had evidence of tumor progression following prior standard of care treatments, and a majority of the patients were heavily pre-treated.
"The encouraging updated Phase 1 dose escalation data of BDC-1001 that was presented at ESMO further support the initiation of our Phase 2 dose-expansion clinical trial in patients with HER2-positive colorectal, breast, endometrial and gastric cancers," said Edith A. Perez, M.D., Chief Medical Officer of Bolt Therapeutics. "We look forward to presenting initial data from the Phase 2 dose-expansion trial in 2024."
"The updated data from the Phase 1 dose-escalation study continue to provide clinical validation of ISACs as a potential therapeutic approach using BDC-1001 to treat patients with HER2-expressing tumors," said Bob T. Li., M.D., Ph.D., MPH, medical oncologist, and principal investigator at Memorial Sloan Kettering Cancer Center (MSK).
Key findings from the updated Phase 1 BDC-1001 dose escalation study are summarized below.
<ul>
<li>Improved BDC-1001 efficacy was observed since the data presented at ASCO in June 2023 with one new CR, two additional long-term SDs, and three patients who received therapy for at least one year.</li>
<li>At the RP2D, one CR was observed in the monotherapy arm in a patient with salivary gland cancer and three PRs were observed at the RP2D; one in the monotherapy arm in a patient with biliary tract cancer and two in the combination arm in patients with colorectal and ovarian cancer. The response rate at the RP2D was 29% in evaluable patients with HER2-positive tumors, both in monotherapy (2/7, 29%) and in combination with nivolumab (2/7, 29%).</li>
<li>At the RP2D, among evaluable patients with HER2-positive tumors, 43% (3/7) in the monotherapy arm and 57% (4/7) in the combination arm experienced at least 24 weeks of disease control, and 57% (4/7) in the monotherapy arm and 71% (5/7) in the combination arm achieved tumor shrinkage.</li>
<li>BDC-1001 continues to be well tolerated at all dose levels and schedules as both monotherapy and in combination with nivolumab with no increase in toxicity in combination with BDC-1001. The most frequent drug-related treatment-emergent adverse events (TEAEs) were grade 1 or 2 infusion-related reactions, which were observed in 29.8% of subjects. Grade 3 or higher treatment-related TEAEs were seen in ten subjects (7.6%), with only one grade 4 and no grade 5 drug-related AEs.</li>
<li>Pharmacodynamic responses in both plasma and tissue were consistent with the mechanism of action for an ISAC. Statistically significant upregulation of TLR signaling pathway gene signature, innate immunity gene signatures and T cell inflamed phenotype was observed in the four patients with clinical benefit. Increases in innate immunity signatures was observed in patients in the q2w cohorts, but not q1w.</li>
<li>The once-weekly dosing cohorts experienced higher rates of adverse events versus every-two-week (q2w) dosing, including: grade 3 or higher BDC-1001-related TEAEs (10.0% versus 2.6%), grade 3 or higher LVEF decreases (7.5% versus 2.6%), and infusion-related reactions (40.0% versus 28.2%), providing further support for the selection of 20 mg/kg q2w as the RP2D.</li>
</ul>
Details about the presentation can be found below and on the ESMO website. Additionally, a copy of the presentation is available on the Publications page of the Bolt Therapeutics website.
<ul>
<li>Title: Recommended phase 2 dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors</li>
<li>Presenter: Bob Li, M.D., Ph.D., MPH, medical oncologist, and principal investigator at MSK</li>
<li>Presentation number: 657MO</li>
<li>Presentation session: Developmental therapeutics</li>
<li>Details: Monday, October 23, 2023, 10:30 a.m. – 12:00 p.m. EDT &nbsp;</li>
</ul>
About BDC-1001
Bolt Biotherapeutics' lead program, BDC-1001, is a human epidermal growth factor receptor 2 (HER2) ISAC comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist. Following the successful completion of the BDC-1001 dose-escalation trial for the treatment of patients with HER2-expressing solid tumors, Bolt is now conducting two Phase 2 clinical trials in the U.S., Europe, and South Korea: NCT04278144 for patients with colorectal, endometrial, and gastroesophageal cancers and NCT05954143 for patients with breast cancer.
About the Boltbody&#x2122; Immune-Stimulating Antibody Conjugate (ISAC) Platform
Bolt Biotherapeutics' Boltbody ISAC platform harnesses the precision of antibodies with the power of the innate and adaptive immune system to reprogram the tumor microenvironment to generate a productive anti-cancer response. Each Boltbody ISAC candidate comprises a tumor-targeting antibody, a non-cleavable linker and a proprietary immune stimulant. The antibody is designed to target one or more markers on the surface of a tumor cell, and the immune stimulant is designed to recruit and activate myeloid cells. Activated myeloid cells initiate a positive feedback loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This increases the population of activated immune system cells in the tumor microenvironment and promotes a robust immune response with the goal of generating durable therapeutic responses for patients with cancer.

Events

Bolt Biotherapeutics Presents Updated Clinical Data From Phase 1 Dose-Escalation Trial Of BDC-1001 As Monotherapy And In Combination With Nivolumab In HER2-Expressing Tumors At ESMO 2023 Congress

Bolt Biotherapeutics Announces First Patient Dosed In Phase 1/2 Study Of BDC-3042 In Patients With Advanced Cancers

Bolt Biotherapeutics Announced That Updated Clinical Data From Its Phase 1/2 Dose-escalation Study Of BDC-1001 Will Be Presented In A Mini-oral Presentation At The European Society For Medical Oncology Congress 2023

<h3>Gainers</h3>
<ul>
<li>AERWINS Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/awin#NASDAQ">AWIN</a>) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not limited to possible sale/other disposition of assets.</li>
<li>RVL Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvlp#NASDAQ">RVLP</a>) shares rose 24.5% to $0.1078 in pre-market trading after gaining over 10% on Friday.</li>
<li>Better Choice Company Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bttr#NYSE">BTTR</a>) shares gained 21.4% to $0.1505 in pre-market trading after gaining 5% on Friday.</li>
<li>Bionomics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnox#NASDAQ">BNOX</a>) shares rose 21.1% to $3.27 in pre-market trading after falling 20% on Friday.</li>
<li>Athena Consumer Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acaq#NASDAQ">ACAQ</a>) shares surged 20.4% to $8.98 in pre-market trading after falling 20% on Friday.</li>
<li>EMCORE Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/emkr#NASDAQ">EMKR</a>) rose 19.7% to $0.5691 in pre-market trading after falling 5% on Friday.</li>
<li>Syndax Pharmaceuticals, Inc.. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sndx#NASDAQ">SNDX</a>) gained 13.6% to $16.50 in pre-market trading. Syndax will share topline results from the pivotal AUGMENT-101 trial in patients with relapsed/refractory KMT2Ar acute leukemia on Oct. 2, 2023.</li>
<li>Bitfarms Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bitf#NASDAQ">BITF</a>) shares climbed 13.1% to $1.21 in pre-market trading.</li>
<li>Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) rose 11.1% to $3.31 in pre-market trading. Femasys shares jumped 46% on Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.</li>
<li>Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares jumped 10.4% to $3.28 in pre-market trading after the company entered into agreement with Lantern Bioworks for replacement-therapy assets.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>SmileDirectClub, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdc#NASDAQ">SDC</a>) fell 64.1% to $0.1489 in pre-market trading. SmileDirectClub filed for bankruptcy just a few years after its remarkable $1.35 billion IPO.</li>
<li>Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) fell 23.8% to $0.80 in pre-market trading after declining 7% on Friday.</li>
<li>Context Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cntx#NASDAQ">CNTX</a>) shares fell 15.8% to $1.27 in pre-market trading after jumping around 19% on Friday.</li>
<li>Nexalin Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxl#NASDAQ">NXL</a>) fell 14.7% to $0.3752 in pre-market trading. On Sept. 21, 2023, Marilyn Elson submitted her resignation as CFO Of Nexalin Technology.</li>
<li>ReShape Lifesciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rsls#NASDAQ">RSLS</a>) shares fell 14.2% to $0.2901 in pre-market trading after declining 23% on Friday. ReShape Lifesciences reported pricing of $3.0 million public offering.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) fell 9.8% to $5.02 in pre-market trading. Brooge Energy said revenue jumped 122% year-over-year to $62.9 million for the first six months ending June 30, 2023.</li>
<li>Danaher Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dhr#NYSE">DHR</a>) shares fell 9.6% to $224.32 in pre-market trading. Danaher said it completed separation of Veralto Corporation.</li>
<li>Siyata Mobile Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/syta#NASDAQ">SYTA</a>) fell 9.6% to $2.55 in pre-market trading.</li>
<li>Grom Social Enterprises Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grom#NASDAQ">GROM</a>) fell 8% to $1.26 in pre-market trading. Grom Social recently priced a $3 million offering.</li>
<li>Bolt Biotherapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bolt#NASDAQ">BOLT</a>) fell 7.7% to $0.96 in pre-market. The FDA recently granted Orphan Drug Designation for Bolt Biotherapeutics&#39; BDC-1001 for gastric cancer, including gastroesophageal junction cancer.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/10/35022955/nio-li-auto-and-3-stocks-to-watch-heading-into-monday"> Nio, Li Auto And 3 Stocks To Watch Heading Into Monday</a>

BNOX: 700% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/34968187">Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)</a>
PTON: 39% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/34959283">Peloton shares are trading higher after the company and Lululemon announced a five-year strategic global partnership.</a>
BOLT: 27% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/34970083">Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers</a>

PTON

Market-Moving News for September 28th

The FDA Has Granted Orphan Drug Designation For Bolt Biotherapeutics' BDC-1001 For Gastric Cancer, Including Gastroesophageal Junction Cancer

Bolt Biotherapeutics Announces Issuance Of US Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

HC Wainwright &amp; Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Buy and maintains $8 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price Target

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.48) per share. This is a 21.31 percent increase over losses of $(0.61) per share from the same period last year. The company reported $1.43 million in sales this quarter. This is a 2.87 percent increase over sales of $1.39 million the same period last year.

Bolt Biotherapeutics Q2 EPS $(0.48) Up From $(0.61) YoY, Sales $1.43M Up From $1.39M YoY

Bolt Biotherapeutics Announced That The First Patients Have Been Dosed In Phase 2 Dose-expansion Trial Of BDC-1001 For HER2-Positive Colorectal, Endometrial, And Gastroesophageal Cancers

Frank Lee, Board Member at Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), reported a large acquisition of company stock options on June 14, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001641281/000120919123037109//Archives/edgar/data/1641281/000120919123037109/0001209191-23-037109-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Lee, Board Member at Bolt Biotherapeutics, a company in the Health Care sector, was just awarded stock options worth 25,000 shares of BOLT. The options give Lee the right to buy the company's stock at $1.63 per share.
Bolt Biotherapeutics shares are trading down 0.66% at $1.5 at the time of this writing on Thursday morning. Since the current price is $1.5, this makes Lee's 25,000 shares worth $37,500.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001641281">Check Out The Full List Of Bolt Biotherapeutics's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member at Bolt Biotherapeutics Acquires Company Stock Options Worth 25,000 Shares

BRIAN OCALLAGHAN, Director at Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), reported a large acquisition of company stock options on June 14, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001641281/000120919123037113//Archives/edgar/data/1641281/000120919123037113/0001209191-23-037113-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that OCALLAGHAN, Director at Bolt Biotherapeutics, a company in the Health Care sector, was just awarded stock options worth 25,000 shares of BOLT. The options give OCALLAGHAN the right to buy the company's stock at $1.63 per share.
Bolt Biotherapeutics shares are trading down 0.66% at $1.5 at the time of this writing on Thursday morning. Since the current price is $1.5, this makes OCALLAGHAN's 25,000 shares worth $37,500.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001641281">Check Out The Full List Of Bolt Biotherapeutics's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director at Bolt Biotherapeutics Acquires Company Stock Options Worth 25,000 Shares

NICOLE ONETTO, Board Member at Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), reported a large acquisition of company stock options on June 14, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001641281/000120919123037115//Archives/edgar/data/1641281/000120919123037115/0001209191-23-037115-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that ONETTO, Board Member at Bolt Biotherapeutics, a company in the Health Care sector, was just awarded stock options worth 25,000 shares of BOLT. The options give ONETTO the right to buy the company's stock at $1.63 per share.
Bolt Biotherapeutics shares are trading down 0.66% at $1.5 at the time of this writing on Thursday morning. Since the current price is $1.5, this makes ONETTO's 25,000 shares worth $37,500.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001641281">Check Out The Full List Of Bolt Biotherapeutics's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bolt Biotherapeutics Board Member Awarded $37K Worth of Stock Options

Bolt Biotherapeutics GAAP EPS of -$0.43 beats by $0.03, revenue of $2.5M beats by $0.74M

H.C. Wainwright analyst Edward White reiterated a Buy rating on Bolt Biotherapeutics (BOLT – Research Report) today and set a price target of $8.00...

Promising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt Biotherapeutics

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bolt Biotherapeutics (BOLT – Research Report), Matin...

Analysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AN2 Therapeutics, Inc. (ANTX – Research Report), Pli...

Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), Pliant Therapeutics (PLRX) and Bolt Biotherapeutics (BOLT)

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Bolt Biotherapeutics (BOLT – Research Report). The associated price tar...

Bolt Biotherapeutics' BDC-1001: A Promising Future in Oncology Drives Buy Rating

Bolt Biotherapeutics GAAP EPS of -$0.47 in-line, revenue of $2.1M beats by $0.31M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bolt Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bolt-stock-quote/">BOLT</a>) just reported results for the fourth quarter of 2023.<ul><li>Bolt Biotherapeutics reported earnings per share of -47 cents. This was above the analyst estimate for EPS of -48 cents.</li><li>The company reported revenue of $2.09 million.</li><li>This was 22.16% better than the analyst estimate for revenue of $1.71 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/bolt-stock-earnings-bolt-biotherapeutics-for-q4-of-2023/">BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioNTech SE (BNTX – Research Report), Intuitive Surgical (ISRG – ...

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on BOLT stock, giving a Buy rating on March 22. Daina Graybosch has gi...

Bolt Biotherapeutics' Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Bolt Biotherapeutics (BOLT – Research Report). The associated price target i...

Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability

ANTX

BNTX

ISRG

MTNB

PLRX

Press Releases

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meeting

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Bolt Biotherapeutics Stock (NASDAQ:BOLT), Short Interest Report

People Also Watch